Amgen's point of view on epoetins.
Seidenberg
Beth
B
Global Development, Amgen, Thousand Oaks, CA, USA.
Perlmutter
Roger M
RM
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D018450:Disease Progression; D004345:Drug Industry; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use*; D006291:Health Policy; D006397:Hematinics / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D040541:Marketing; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012449:Safety; D012955:Societies, Medical; D016019:Survival Analysis; D016896:Treatment Outcome
D006397:Hematinics; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068817:Epoetin Alfa